Telix (ASX:TLX) share price jumps 30% to an all-time high. Here's why.

The Telix Pharmaceuticals Ltd (ASX: TLX) share price jumped more than 30% higher today following news of a major partnership.

| More on:
man jumping along increasing bar graph signifying jump in alumina share price

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Telix Pharmaceuticals Ltd (ASX: TLX) share price has started the week with a bang, rocketing by more than 30% today in welcome news for shareholders.

Telix released a positive announcement during mid-afternoon trade, sending its shares to a new record. Shares in the biopharma company later pulled back just slightly to close the day up 28.96% at $2.16. 

Let's take a look and see why the market responded so positively to Telix today.  

Landmark deal

According to the release, Telix advised it has entered a strategic commercial partnership with China Grand Pharmaceutical and Healthcare Holdings (CGP). The milestone agreement will see China Grand Pharmaceutical have access to Telix's portfolio of molecularly-targeted radiation products (MTR).

China Grand has been chosen as Telix's exclusive partner for the Greater China market. The deal includes the development and commercialisation rights to Telix's prostate, renal and brain cancer imaging and therapeutics MTR products.

The deal in detail

Under the agreement, China Grand will provide an up-front payment of US$25 million to Telix. The credit does not consist of any future regulatory and commercial milestone payments.

Up to US$225 million is available in payments relating to key targets being met. They include up to US$69 million in attaining marketing authorisation from the National Medical Product Administration in China. Furthermore, up to US$156 million will be paid to Telix if net sales performance across the region is met during the term of the agreement.

China Grand Pharmaceutical will invest US$65 million in clinical costs to help develop Telix's prostate and renal cancer products in China.

Royalties on therapeutic product sales will paid in addition to the milestone payments.

The initial term of the deal is valid for 10 years from the commencement date of each product being granted marketing authorisation.

Strategic equity investment

China Grand will make a strategic equity investment of US$25 million in the private placement of 20,947,181 fully paid ordinary Telix shares. The shares will be issued at a price of $1.69 and locked to a holding period of no less than 12 months.

Management commentary

Telix CEO Dr Chris Behrenbruch commented on the partnership:

Telix's mission is to be a leading global oncology company and China is an important future market for our products. We are pleased to be working with CGP to deliver our diagnostic imaging and therapeutic products to cancer patients in China.

We believe that CGP possesses the technical experience and execution infrastructure to be an ideal clinical and commercial partner for Telix in China.

China Grand executive deputy officer Mr Frank Zhou added:

China Grand Pharma has a strong commitment to oncology, including radioactive products, in China and around the globe.

We firmly believe in the potential of Telix's product portfolio to have a significant clinical impact in China. It is an honour for us to have the right to bring Telix's unique product range to our doctors and patients with major unmet medical needs. At the same time, our close clinical involvement will help bring strength to Telix's product development and reach. We are very excited about this long-term partnership.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the 'five best ASX stocks' for investors to buy right now. We believe these stocks are trading at attractive prices and Scott thinks they could be great buys right now...

See The 5 Stocks *Returns as of 30 April 2025

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

A man looking at his laptop and thinking.
Share Gainers

Here are the top 10 ASX 200 shares today

The markets lost their steam this Thursday.

Read more »

A young man pointing up looking amazed, indicating a surging share price movement for an ASX company
Broker Notes

3 amazing ASX 200 shares to buy and hold forever

Brokers think these shares are in the buy zone. Let's see why they could be top buy and hold picks.

Read more »

iPhone with the logo and the word Google spelt multiple times in the background.
Opinions

I've been buying these 2 US stocks in 2025. Here's why

Sometimes the US markets are a better place to go shopping for stocks.

Read more »

Ecstatic woman looking at her phone outside with her fist pumped.
Share Gainers

Why Catapult, Hutchinson, SKS, and West African shares are pushing higher today

These shares are having a strong session despite the market weakness.

Read more »

A man sits in despair at his computer with his hands either side of his head, staring into the screen with a pained and anguished look on his face, in a home office setting.
Share Fallers

Why Dexus, Mayne Pharma, Nufarm, and Treasury Wine shares are falling today

These shares are having a tough session on Thursday. But why?

Read more »

A woman sits at her computer with her chin resting on her hand as she contemplates her next potential investment.
Mergers & Acquisitions

IAG share price lifts off on strategic alliance approval

IAG shares are racing higher in Thursday’s sinking market.

Read more »

Rising gold share price represented by a green arrow on piles of gold block.
Gold

Up 72% in 2025, why is this ASX 200 gold stock racing ahead of the benchmark again today?

Investors are bidding up this high-flying ASX 200 gold stock again on Thursday. But why?

Read more »

A woman wearing a black and white striped t-shirt looks to the sky with her hand to her chin contemplating buying ASX shares today as the market rebounds
Share Market News

Where could the RBA interest rate go in the next 12 months?

Here’s what one expert thinks could happen with interest rates by early 2026.

Read more »